{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:02:59Z","timestamp":1792605779303,"version":"4.5.0"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,13]],"date-time":"2023-05-13T00:00:00Z","timestamp":1683936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hellenic Journal of Cardiology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.hjc.2023.05.004","type":"journal-article","created":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T04:06:14Z","timestamp":1684209974000},"page":"73-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["The patient pathway in ATTR-CM in Greece and how to improve it: A\u00a0multidisciplinary perspective"],"prefix":"10.1016","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9940-7473","authenticated-orcid":false,"given":"Efstratios A.","family":"Apostolou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Maria","family":"Fontrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios K.","family":"Efthimiadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8191-5832","authenticated-orcid":false,"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5375-1789","authenticated-orcid":false,"given":"John","family":"Parissis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9518-3089","authenticated-orcid":false,"given":"Panos","family":"Kanavos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.hjc.2023.05.004_bib1","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ahj.2012.04.015","article-title":"Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS)","volume":"164","author":"Ruberg","year":"2012","journal-title":"Am Heart J"},{"issue":"10","key":"10.1016\/j.hjc.2023.05.004_bib2","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","article-title":"Transthyretin (TTR) cardiac amyloidosis","volume":"126","author":"Ruberg","year":"2012","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.hjc.2023.05.004_bib3","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/nrcardio.2010.67","article-title":"Transthyretin-related amyloidoses and the heart: a clinical overview","volume":"7","author":"Rapezzi","year":"2010","journal-title":"Nat Rev Cardiol"},{"issue":"6","key":"10.1016\/j.hjc.2023.05.004_bib4","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ejhf.2198","article-title":"Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"12 Suppl 3","key":"10.1016\/j.hjc.2023.05.004_bib5","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3949\/ccjm.84.s3.02","article-title":"Cardiac amyloidosis: an update on diagnosis and treatment","volume":"84","author":"Donnelly","year":"2017","journal-title":"Cleve Clin J Med"},{"issue":"21","key":"10.1016\/j.hjc.2023.05.004_bib6","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","article-title":"Diagnosis, prognosis, and therapy of transthyretin amyloidosis","volume":"66","author":"Gertz","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.hjc.2023.05.004_bib7","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20140155","article-title":"Amyloidogenic and non-amyloidogenic transthyretin variants interact differently with human cardiomyocytes: insights into early events of non-fibrillar tissue damage","volume":"35","author":"Manral","year":"2015","journal-title":"Biosci Rep"},{"issue":"4","key":"10.1016\/j.hjc.2023.05.004_bib8","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1152\/physiol.00047.2015","article-title":"Viewing extrinsic proteotoxic stress through the lens of amyloid cardiomyopathy","volume":"31","author":"Sapp","year":"2016","journal-title":"Physiology"},{"issue":"9","key":"10.1016\/j.hjc.2023.05.004_bib9","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/j.bpj.2016.09.010","article-title":"Biochemical and electrophysiological modification of amyloid transthyretin on cardiomyocytes","volume":"111","author":"Sartiani","year":"2016","journal-title":"Biophys J"},{"issue":"38","key":"10.1016\/j.hjc.2023.05.004_bib10","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","author":"Casta\u00f1o","year":"2017","journal-title":"Eur Heart J"},{"issue":"38","key":"10.1016\/j.hjc.2023.05.004_bib11","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.hjc.2023.05.004_bib12","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1002\/ejhf.2589","article-title":"Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis","volume":"24","author":"Antonopoulos","year":"2022","journal-title":"Eur\u00a0J Heart Fail"},{"issue":"12","key":"10.1016\/j.hjc.2023.05.004_bib13","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/ejhf.2532","article-title":"Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies","volume":"24","author":"Aimo","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"10.1016\/j.hjc.2023.05.004_bib14","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.hjc.2023.05.004_bib15","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3109\/07853890.2015.1068949","article-title":"Evolving landscape in the management of transthyretin amyloidosis","volume":"47","author":"Hawkins","year":"2015","journal-title":"Ann Med"},{"issue":"1","key":"10.1016\/j.hjc.2023.05.004_bib16","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.hjc.2023.05.004_bib17","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1161\/CIRCULATIONAHA.116.024438","article-title":"Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis","volume":"135","author":"Maurer","year":"2017","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.hjc.2023.05.004_bib18","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.acvd.2013.06.051","article-title":"Cardiac amyloidosis: updates in diagnosis and management","volume":"106","author":"Mohty","year":"2013","journal-title":"Arch Cardiovasc Dis"},{"issue":"2","key":"10.1016\/j.hjc.2023.05.004_bib19","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.cardfail.2017.12.005","article-title":"Time course of common clinical manifestations in patients with transthyretin cardiac amyloidosis: delay from symptom onset to diagnosis","volume":"24","author":"Papoutsidakis","year":"2018","journal-title":"J\u00a0Card Fail"},{"issue":"7","key":"10.1016\/j.hjc.2023.05.004_bib20","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/eurheartj\/ehs123","article-title":"Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective","volume":"34","author":"Rapezzi","year":"2013","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.hjc.2023.05.004_bib21","article-title":"Senile systemic amyloidosis: clinical features at presentation and outcome","volume":"2","author":"Pinney","year":"2013","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"10","key":"10.1016\/j.hjc.2023.05.004_bib22","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"24","key":"10.1016\/j.hjc.2023.05.004_bib23","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/eurheartj\/ehx043","article-title":"Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths","volume":"38","author":"Gonz\u00e1lez-L\u00f3pez","year":"2017","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.hjc.2023.05.004_bib24","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/HCO.0000000000000547","article-title":"Amyloidosis cardiomyopathy: update in the diagnosis and treatment of the most common types","volume":"33","author":"Nativi-Nicolau","year":"2018","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.hjc.2023.05.004_bib25","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1750-1172-8-31","article-title":"Guideline of transthyretin-related hereditary amyloidosis for clinicians","volume":"8","author":"Ando","year":"2013","journal-title":"Orphanet J Rare Dis"},{"issue":"7","key":"10.1016\/j.hjc.2023.05.004_bib26","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1056\/NEJM199702133360703","article-title":"Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans","volume":"336","author":"Jacobson","year":"1997","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.hjc.2023.05.004_bib27","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.tcm.2017.07.004","article-title":"Cardiac amyloidosis: an update on pathophysiology, diagnosis, and treatment","volume":"28","author":"Siddiqi","year":"2018","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.hjc.2023.05.004_bib28","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/B978-0-444-52902-2.00038-2","article-title":"Transthyretin familial amyloid polyneuropathy","volume":"115","author":"Plant\u00e9-Bordeneuve","year":"2013","journal-title":"Handb Clin Neurol"},{"issue":"9","key":"10.1016\/j.hjc.2023.05.004_bib29","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis","volume":"12","author":"Maurer","year":"2019","journal-title":"Circ Heart Fail"},{"issue":"12","key":"10.1016\/j.hjc.2023.05.004_bib30","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.cardfail.2016.10.008","article-title":"Transthyretin cardiac amyloidosis in older Americans","volume":"22","author":"Brunjes","year":"2016","journal-title":"J\u00a0Card Fail"},{"issue":"11","key":"10.1016\/j.hjc.2023.05.004_bib31","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0002-9149(97)82785-3","article-title":"Symptomatic conduction system disease in cardiac amyloidosis","volume":"80","author":"Mathew","year":"1997","journal-title":"Am J Cardiol"},{"issue":"sup1","key":"10.1016\/j.hjc.2023.05.004_bib32","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/13506129.2016.1272453","article-title":"Standard heart failure medication in cardiac transthyretin amyloidosis: useful or harmful?","volume":"24","author":"Aus dem Siepen","year":"2017","journal-title":"Amyloid"},{"issue":"Suppl 1","key":"10.1016\/j.hjc.2023.05.004_bib33","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3109\/13506129.2011.574354059","article-title":"Clinical features and survival in senile systemic amyloidosis: comparison to familial transthyretin cardiomyopathy","volume":"18","author":"Connors","year":"2011","journal-title":"Amyloid"},{"issue":"1","key":"10.1016\/j.hjc.2023.05.004_bib34","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1185\/03007995.2012.754348","article-title":"THAOS - the Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis","volume":"29","author":"Coelho","year":"2013","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"10.1016\/j.hjc.2023.05.004_bib35","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3109\/13506129.2015.1135792","article-title":"Carpal tunnel syndrome: a common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosis","volume":"23","author":"Nakagawa","year":"2016","journal-title":"Amyloid"},{"issue":"3","key":"10.1016\/j.hjc.2023.05.004_bib36","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1161\/CIRCULATIONAHA.115.018852","article-title":"Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study","volume":"133","author":"Connors","year":"2016","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.hjc.2023.05.004_bib37","article-title":"Updates in cardiac amyloidosis: a review","volume":"1","author":"Banypersad","year":"2012","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"10","key":"10.1016\/j.hjc.2023.05.004_bib38","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1001\/jama.2017.9236","article-title":"Association between ruptured distal biceps tendon and wild-type transthyretin cardiac amyloidosis","volume":"318","author":"Geller","year":"2017","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.hjc.2023.05.004_bib39","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1080\/13506129.2017.1375908","article-title":"Hip and knee arthroplasty are common among patients with transthyretin cardiac amyloidosis, occurring years before cardiac amyloid diagnosis: can we identify affected patients earlier?","volume":"24","author":"Rubin","year":"2017","journal-title":"Amyloid"},{"issue":"30","key":"10.1016\/j.hjc.2023.05.004_bib40","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A\u00a0new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.hjc.2023.05.004_bib41","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jaccao.2020.06.007","article-title":"Diuretic dose and NYHA functional class are independent predictors of mortality in patients with transthyretin cardiac amyloidosis","volume":"2","author":"Cheng","year":"2020","journal-title":"JACC CardioOncol"},{"issue":"6","key":"10.1016\/j.hjc.2023.05.004_bib42","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1002\/ehf2.12989","article-title":"Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage","volume":"7","author":"Law","year":"2020","journal-title":"ESC Heart Fail"},{"issue":"1","key":"10.1016\/j.hjc.2023.05.004_bib43","first-page":"e288","article-title":"Mode of death in cardiac amyloidosis","volume":"11","author":"Kharoubi","year":"2019","journal-title":"Arch Cardiovasc Dis Suppl"},{"issue":"6","key":"10.1016\/j.hjc.2023.05.004_bib44","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1002\/ehf2.12986","article-title":"Heart failure from ATTRwt amyloid cardiomyopathy is associated with poor prognosis","volume":"7","author":"Kocher","year":"2020","journal-title":"ESC Heart Fail"},{"issue":"2","key":"10.1016\/j.hjc.2023.05.004_bib45","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s40120-018-0106-z","article-title":"Characterizing the high disease burden of transthyretin amyloidosis for patients and caregivers","volume":"7","author":"Stewart","year":"2018","journal-title":"Neurol Ther"},{"issue":"Suppl 1","key":"10.1016\/j.hjc.2023.05.004_bib46","doi-asserted-by":"crossref","first-page":"O26","DOI":"10.1186\/1750-1172-10-S1-O26","article-title":"Quality of life in ATTR amyloidosis","volume":"10","author":"Lane","year":"2015","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"10.1016\/j.hjc.2023.05.004_bib47","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1002\/ehf2.13913","article-title":"Healthcare resource use of patients with transthyretin amyloid cardiomyopathy","volume":"9","author":"Lauppe","year":"2022","journal-title":"ESC Heart Fail"},{"issue":"21","key":"10.1016\/j.hjc.2023.05.004_bib48","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1136\/heartjnl-2012-301924","article-title":"Cardiac transthyretin amyloidosis","volume":"98","author":"Dungu","year":"2012","journal-title":"Heart"},{"issue":"8","key":"10.1016\/j.hjc.2023.05.004_bib49","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/j.cardfail.2019.07.197","article-title":"Amyloidosis research consortium cardiac amyloidosis survey: results from patients with AL and ATTR amyloidosis and their caregivers","volume":"25","author":"Lousada","year":"2019","journal-title":"J\u00a0Card Fail"},{"issue":"1","key":"10.1016\/j.hjc.2023.05.004_bib50","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1017\/S1041610210000785","article-title":"Relative importance of patient disease indicators on informal care and caregiver burden in Alzheimer's disease","volume":"23","author":"Bergvall","year":"2011","journal-title":"Int Psychogeriatr"},{"issue":"1","key":"10.1016\/j.hjc.2023.05.004_bib51","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1016\/j.crvasa.2012.11.018","article-title":"Cardiac amyloidosis: a comprehensive review","volume":"55","author":"Fikrle","year":"2013","journal-title":"Cor Vasa"},{"issue":"19","key":"10.1016\/j.hjc.2023.05.004_bib52","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1016\/j.jacc.2018.03.022","article-title":"Multimorbidity in older adults with cardiovascular disease","volume":"71","author":"Forman","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.hjc.2023.05.004_bib53","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10741-015-9480-0","article-title":"Cardiac amyloidosis: the great pretender","volume":"20","author":"Rapezzi","year":"2015","journal-title":"Heart Fail Rev"},{"issue":"1","key":"10.1016\/j.hjc.2023.05.004_bib54","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s40119-021-00219-5","article-title":"Impact of delayed diagnosis and misdiagnosis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM): a targeted literature review","volume":"10","author":"Rozenbaum","year":"2021","journal-title":"Cardiol Ther"},{"issue":"8","key":"10.1016\/j.hjc.2023.05.004_bib55","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.cardfail.2017.07.113","article-title":"A\u00a0survival analysis of subjects with transthyretin amyloid cardiomyopathy from the transthyretin amyloidosis outcomes survey","volume":"23","author":"Grogan","year":"2017","journal-title":"J\u00a0Card Fail"},{"issue":"2","key":"10.1016\/j.hjc.2023.05.004_bib56","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey)","volume":"68","author":"Maurer","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.hjc.2023.05.004_bib57","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1016\/j.mayocp.2021.04.021","article-title":"Early diagnosis and outcome in patients with wild-type transthyretin cardiac amyloidosis","volume":"96","author":"Fumagalli","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.hjc.2023.05.004_bib58","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ijcard.2019.12.063","article-title":"Diagnostic delay in wild type transthyretin cardiac amyloidosis - A clinical challenge","volume":"304","author":"Ladefoged","year":"2020","journal-title":"Int J Cardiol"},{"issue":"5","key":"10.1016\/j.hjc.2023.05.004_bib59","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.amjmed.2020.11.031","article-title":"Cardiac Amyloidosis for\u00a0the primary care provider: a practical review to promote earlier recognition of disease","volume":"134","author":"Zhang","year":"2021","journal-title":"Am J Med"},{"issue":"14","key":"10.1016\/j.hjc.2023.05.004_bib60","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.2217\/cer-2022-0074","article-title":"Clinical manifestations and healthcare utilization before diagnosis of transthyretin amyloidosis","volume":"11","author":"Nativi-Nicolau","year":"2022","journal-title":"J\u00a0Comp Eff Res"},{"issue":"10","key":"10.1016\/j.hjc.2023.05.004_bib61","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s12325-015-0250-0","article-title":"Light chain amyloidosis: patient experience survey from the amyloidosis research consortium","volume":"32","author":"Lousada","year":"2015","journal-title":"Adv Ther"},{"issue":"8","key":"10.1016\/j.hjc.2023.05.004_bib62","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.ejim.2013.10.007","article-title":"Systemic amyloidoses: what an internist should know","volume":"24","author":"Palladini","year":"2013","journal-title":"Eur J Intern Med"},{"issue":"2","key":"10.1016\/j.hjc.2023.05.004_bib63","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jchf.2013.11.004","article-title":"Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction","volume":"2","author":"Mohammed","year":"2014","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.hjc.2023.05.004_bib64","unstructured":"Council recommendation on an action in the field of rare diseases (2009\/C 151\/02). Published online June 2009. https:\/\/eur-lex.europa.eu\/LexUriServ\/LexUriServ.do?uri=OJ:C:2009:151:0007:0010:EN:PDF. Accessed May 25, 2022."},{"key":"10.1016\/j.hjc.2023.05.004_bib65","unstructured":"Department of Health and Social Care. UK Rare Diseases Framework. Published online 2021. http:\/\/eur-lex.europa.eu\/LexUriServ\/LexUriServ.do?uri=OJ:C:2009:151:0007:0010:EN:PDF."},{"key":"10.1016\/j.hjc.2023.05.004_bib66","unstructured":"Kole A, Hedley V. Recommendations from the Rare 2030 Foresight Study: The future of rare diseases starts today. Published online February 2021. May 25, 2022. https:\/\/www.rare2030.eu\/recommendations\/."},{"issue":"16","key":"10.1016\/j.hjc.2023.05.004_bib67","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hjc.2023.05.004_bib68","unstructured":"Greek Network of Precision Medicine in Cardiology. https:\/\/icardiacnet.gr. Accessed March 20, 2023."},{"issue":"2","key":"10.1016\/j.hjc.2023.05.004_bib69","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.recesp.2019.12.017","article-title":"Clinical profile and outcome of cardiac amyloidosis in a Spanish referral center","volume":"74","author":"L\u00f3pez-Sainz","year":"2021","journal-title":"Rev Esp Cardiol"},{"issue":"5","key":"10.1016\/j.hjc.2023.05.004_bib70","doi-asserted-by":"crossref","DOI":"10.1212\/NXG.0000000000200013","article-title":"High hereditary transthyretin-related amyloidosis prevalence in Crete: genetic heterogeneity and distinct phenotypes","volume":"8","author":"Tzagournissakis","year":"2022","journal-title":"Neurol Genet"},{"key":"10.1016\/j.hjc.2023.05.004_bib71","doi-asserted-by":"crossref","DOI":"10.1177\/11795468211015230","article-title":"Best practices in specialized amyloidosis centers in the United States: a survey of cardiologists, nurses, patients, and patient advocates","volume":"15","author":"Nativi-Nicolau","year":"2021","journal-title":"Clin Med Insights Cardiol"},{"issue":"2","key":"10.1016\/j.hjc.2023.05.004_bib72","doi-asserted-by":"crossref","DOI":"10.2196\/12901","article-title":"Understanding the use and perceived impact of a medical podcast: qualitative study","volume":"5","author":"Malecki","year":"2019","journal-title":"JMIR Med Educ"},{"issue":"7","key":"10.1016\/j.hjc.2023.05.004_bib73","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1007\/s11606-019-05606-2","article-title":"Medical education podcasts: where we are and questions unanswered","volume":"35","author":"Berk","year":"2020","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.hjc.2023.05.004_bib74","series-title":"Surveillance of the number of doctors and dentists: Year 2020","year":"2021"},{"key":"10.1016\/j.hjc.2023.05.004_bib75","unstructured":"Greek Government. Law 4931\/2022, FEK 94\/\u0391\/13-5-2022.2022."},{"key":"10.1016\/j.hjc.2023.05.004_bib76","series-title":"England Rare Diseases Action Plan","year":"2022"},{"key":"10.1016\/j.hjc.2023.05.004_bib77","unstructured":"Department of Health, Ireland. National Rare Disease Plan for Ireland, 2014-2018. Published online 2014. https:\/\/assets.gov.ie\/37342\/da70fc6fadd24425b98311e679f4406b.pdf."},{"key":"10.1016\/j.hjc.2023.05.004_bib78","unstructured":"Greek Government. Greece's recovery and resilience plan. Published 2021. May\u00a030, 2022. https:\/\/ec.europa.eu\/info\/business-economy-euro\/recovery-coronavirus\/recovery-and-resilience-facility\/greeces-recovery-and-resilience-plan_en."},{"issue":"12","key":"10.1016\/j.hjc.2023.05.004_bib79","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1093\/rheumatology\/kex508","article-title":"Can prediction models in primary care enable earlier diagnosis of rare rheumatic diseases?","volume":"57","author":"Pearce","year":"2018","journal-title":"Rheumatology"},{"issue":"Suppl 1","key":"10.1016\/j.hjc.2023.05.004_bib80","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11606-007-0275-4","article-title":"Who is responsible for evaluating the safety and effectiveness of medical devices? The role of independent technology assessment","volume":"23","author":"Feldman","year":"2008","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.hjc.2023.05.004_bib81","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1472-6947-6-22","article-title":"Assessment of the potential impact of a reminder system on the reduction of diagnostic errors: a quasi-experimental study","volume":"6","author":"Ramnarayan","year":"2006","journal-title":"BMC Med Inf Decis Making"},{"key":"10.1016\/j.hjc.2023.05.004_bib82","unstructured":"European Commission. Commission Implementing Decision setting out criteria for establishing and evaluating European Reference Networks. Published online March 2014. https:\/\/ec.europa.eu\/health\/european-reference-networks\/overview_en#latest-updates-and-documents. Accessed May 30, 2022."},{"key":"10.1016\/j.hjc.2023.05.004_bib83","unstructured":"De Santis M, Hervas C, Weinman A, et\u00a0al. Patient Empowerment. Policy Brief. Published online 2018. May 30, 2022. http:\/\/www.rd-action.eu\/wp-content\/uploads\/2018\/09\/PATIENT-EMPOWERMENT.pdf."},{"issue":"Suppl 3","key":"10.1016\/j.hjc.2023.05.004_bib84","first-page":"s591","article-title":"The Italian National Centre for Rare Diseases: where research and public health translate into action","volume":"12","author":"Taruscio","year":"2014","journal-title":"Blood Transfus"},{"key":"10.1016\/j.hjc.2023.05.004_bib85","series-title":"National plan for rare diseases: Denmark","year":"2017"},{"key":"10.1016\/j.hjc.2023.05.004_bib86","unstructured":"EURORDIS Rare Diseases Europe. Major Recommendations shaping RD policy. Published 2018. https:\/\/www.eurordis.org\/content\/new-eu-committee-experts-rare-diseases. Assessed May 2, 2022."},{"issue":"3","key":"10.1016\/j.hjc.2023.05.004_bib87","first-page":"185","article-title":"Establishing patient registries for rare diseases: rationale and challenges","volume":"34","author":"Boulanger","year":"2020","journal-title":"Pharmaceut Med"},{"key":"10.1016\/j.hjc.2023.05.004_bib88","unstructured":"US Food and Drug Administration. Rare diseases: natural history studies for drug development guidance for industry. Published online 2019. https:\/\/www.fda.gov\/media\/122425\/download. Accessed May 2, 2022."},{"key":"10.1016\/j.hjc.2023.05.004_bib89","unstructured":"Orphanet Report Series. Rare Disease Registries in Europe. Published online 2021. https:\/\/www.orpha.net\/orphacom\/cahiers\/docs\/GB\/Registries.pdf."},{"key":"10.1016\/j.hjc.2023.05.004_bib90","unstructured":"Istituto Superiore di Sanita. National Center for rare diseases. https:\/\/www.iss.it\/web\/iss-en\/rare-diseases. Accessed May 30, 2022."}],"container-title":["Hellenic Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1109966623000714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1109966623000714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:16:41Z","timestamp":1761099401000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1109966623000714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":90,"alternative-id":["S1109966623000714"],"URL":"https:\/\/doi.org\/10.1016\/j.hjc.2023.05.004","relation":{},"ISSN":["1109-9666"],"issn-type":[{"value":"1109-9666","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The patient pathway in ATTR-CM in Greece and how to improve it: A\u00a0multidisciplinary perspective","name":"articletitle","label":"Article Title"},{"value":"Hellenic Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hjc.2023.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Hellenic Society of Cardiology. Publishing services by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}